Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Codexis, Inc.NASDAQ: CDXS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 90.77M shares rose 10.1% year over year, behind the +16.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.1% toward the trailing-twelve-month pace of +16.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
90.77M+0.4% QoQ
Last fiscal yearDec 2025
87.14M+18.7% YoY
LTMMar 2026
89.2M+16.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.1%——
1 year+18.7%——
3-year CAGR+10.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
87.14M USD
Year-over-year change
+18.7%
4-year CAGR
+7.8%

Weighted Avg Shares vs competitors

How CDXS compares with its peers on the latest reported figures

  • CDXS's LTM Mar 2026 weighted avg shares of 89.2M shares is the 7th highest of the 10 companies compared; the peer median is 96.61M shares.
  • Its year-over-year change of +16.6% is the 7th highest of 10, against a peer median of +52.9%.
  • Over three fiscal years its annual growth of +10.1% compares with a peer median of +19.3%.
CDXS Competitors Peer median
Weighted Avg Shares for CDXS and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202636.32M +0.4%+1.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
Peer median (excluding CDXS) 96.61M+52.9%+19.3%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue104.75M138.59M70.14M59.35M70.39M
Cost of Revenue22.21M38.03M12.81M16.29M9.34M
Gross Profit82.55M100.56M57.33M43.06M61.05M
Gross Margin78.8%72.6%81.7%72.6%86.7%
Research & Development55.92M80.1M58.89M46.26M52.31M
Selling, General & Admin49.32M52.17M53.25M55.15M47.07M
Operating Expenses105.24M135.44M125.4M101.58M99.38M
Depreciation & Amortization5.95M5.4M5.52M4.95M5.25M
EBITDA(15.14M)(26.31M)(49.28M)(53.41M)(33.87M)
EBITDA Margin-14.5%-19.0%-70.3%-90.0%-48.1%
Operating Income(22.7M)(34.88M)(68.07M)(58.52M)(38.33M)
Operating Margin-21.7%-25.2%-97.0%-98.6%-54.5%
Interest Income459K1.44M4.17M3.67M2.63M
Interest Expense00004.81M
Other Income / Expenses1.61M1.57M(8.1M)(6.72M)(5.6M)
Income Before Tax(21.09M)(33.32M)(76.17M)(65.24M)(43.93M)
Pre-Tax Margin-20.1%-24.0%-108.6%-109.9%-62.4%
Income Tax Expense189K276K69K34K47K
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Net Margin-20.3%-24.2%-108.7%-110.0%-62.5%
EPS (Basic)(0.33)(0.51)(1.12)(0.89)(0.50)
EPS (Diluted)(0.33)(0.51)(1.12)(0.89)(0.50)
Weighted Avg Shares64.57M65.34M68.13M73.41M87.14M
Weighted Avg Shares (Diluted)64.57M65.34M68.13M73.41M87.14M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.